Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Agenus Inc (AGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 399,931
  • Shares Outstanding, K 134,205
  • Annual Sales, $ 36,780 K
  • Annual Income, $ -162,040 K
  • 60-Month Beta 2.09
  • Price/Sales 10.58
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.33
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +26.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.62 +7.63%
on 03/08/19
3.31 -14.80%
on 02/27/19
-0.07 (-2.42%)
since 02/22/19
3-Month
1.95 +44.62%
on 12/26/18
3.88 -27.32%
on 01/18/19
+0.56 (+24.78%)
since 12/21/18
52-Week
1.54 +83.12%
on 10/30/18
5.24 -46.18%
on 03/23/18
-2.37 (-45.66%)
since 03/22/18

Most Recent Stories

More News
Agenus Announces Clinical Appointments

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced new leadership appointments as its...

AGEN : 2.82 (-5.37%)
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.

AGEN : 2.82 (-5.37%)
TRVN : 1.70 (+1.19%)
CELG : 88.15 (-1.65%)
GILD : 63.77 (-1.77%)
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -42.86% and -19.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

AGEN : 2.82 (-5.37%)
Agenus: 4Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Agenus Inc. (AGEN) on Thursday reported a loss of $48.8 million in its fourth quarter.

AGEN : 2.82 (-5.37%)
Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported financial...

AGEN : 2.82 (-5.37%)
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

AGEN : 2.82 (-5.37%)
NVS : 93.42 (-0.26%)
GILD : 63.77 (-1.77%)
GSK : 41.25 (+0.02%)
Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, will release its fourth quarter and full...

AGEN : 2.82 (-5.37%)
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

AGEN : 2.82 (-5.37%)
NVS : 93.42 (-0.26%)
GILD : 63.77 (-1.77%)
GSK : 41.25 (+0.02%)
Analysis: Positioning to Benefit within Micron Technology, Caterpillar, Agenus, Fossil Group, Marathon Petroleum, and Geo Group -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Micron Technology, Inc. (NASDAQ:MU),...

GEO : 18.99 (-1.71%)
AGEN : 2.82 (-5.37%)
MPC : 61.30 (-2.37%)
FOSL : 13.88 (-4.74%)
CAT : 129.77 (-3.20%)
MU : 41.62 (-5.39%)
Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of its...

AGEN : 2.82 (-5.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AGEN with:

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

2nd Resistance Point 3.04
1st Resistance Point 2.93
Last Price 2.82
1st Support Level 2.75
2nd Support Level 2.68

See More

52-Week High 5.24
Fibonacci 61.8% 3.83
Fibonacci 50% 3.39
Fibonacci 38.2% 2.95
Last Price 2.82
52-Week Low 1.54

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar